

Submucosal diclofenac for acute postoperative pain in third molar surgery

Gorecki, Patricia; Rainsford, Kim D.; Taneja, Pankaj ; Bulsara, Yogesh; Pearson, David ; Saund, Daniel ; Ahmed, Bilal ; Dietrich, Thomas

DOI:

[10.1177/0022034517744207](https://doi.org/10.1177/0022034517744207)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Gorecki, P, Rainsford, KD, Taneja, P, Bulsara, Y, Pearson, D, Saund, D, Ahmed, B & Dietrich, T 2018, 'Submucosal diclofenac for acute postoperative pain in third molar surgery: a randomized, controlled clinical trial', *Journal of Dental Research*, vol. 97, no. 4, pp. 381-387. <https://doi.org/10.1177/0022034517744207>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 06/11/2017

Submucosal Diclofenac for Acute Postoperative Pain in Third Molar Surgery: A Randomized, Controlled Clinical Trial
P. Gorecki, K.D. Rainsford, P. Taneja, Y. Bulsara, D. Pearson, D. Saund, B. Ahmed, T. Dietrich,
Journal of Dental Research © International & American Associations for Dental Research 2017
<https://doi.org/10.1177/0022034517744207>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Submucosal Diclofenac for Acute Postoperative Pain in Third Molar Surgery

Journal:	<i>Journal of Dental Research</i>
Manuscript ID	JDR-17-0728.R1
Manuscript Type:	Research Reports
Date Submitted by the Author:	26-Sep-2017
Complete List of Authors:	Gorecki, Patricia; University of Birmingham School of Dentistry, Oral Surgery Rainsford, Kim; Sheffield Hallam University, Biomedical Research Centre Taneja, Pankaj; Birmingham Dental Hospital Bulsara, Yogesh; University of Birmingham School of Dentistry, Oral Surgery Pearson, David; Birmingham Dental Hospital Saund, Daniel; Birmingham Dental Hospital, Oral Surgery Ahmed, Bilal; Birmingham Dental Hospital Dietrich, Thomas; University of Birmingham School of Dentistry, Oral Surgery
Keywords:	Anesthesia, Clinical studies/trials, Oral & Maxillofacial Surgery, Pain, Pharmacology
Abstract:	Diclofenac sodium is a widely used non-steroidal anti-inflammatory drug (NSAID) for relief of inflammatory pain. A recent formulation combines this drug with hydroxypropyl- β -cyclodextrin (HP β CD) to improve its solubility and to enable subcutaneous administration. Previous studies confirmed the efficacy of this combination. This study's aim was to evaluate the efficacy, safety and local tolerability of diclofenac HP β CD administered as a local submucosal injection prior to lower third molar surgery. We conducted a prospective, randomised, double-blind, placebo-controlled, parallel-group phase II single centre study. Seventy-five patients requiring mandibular third molar surgery were randomised into one of five groups: 5mg/1mL diclofenac HP β CD, 12.5mg/1mL diclofenac HP β CD, 25mg/1mL diclofenac HP β CD, 50mg/1mL diclofenac HP β CD or 1mL placebo. The respective study drug was injected into the mucosal tissue surrounding the surgical site prior to surgery following achievement of local anaesthesia. The primary outcome measure was the Area Under the Curve (AUC) of cumulative pain scores over the time from end of surgery to 6 hours post-surgery. This demonstrated a global treatment effect between the active groups and placebo, hence confirming the study drug's efficacy ($p=0.0126$). Secondary outcome measures included the time until onset of pain and the time until patients required rescue medication, both showing statistical significance of the study drug compared to placebo ($p<0.0161$ and $p<0.0001$, respectively). The time until rescue medication ranged between 7.8hrs (for 25mg/1mL diclofenac HP β CD) and 16hrs (for 50mg/1mL diclofenac

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	HPβCD). Interestingly, the 5mg/1mL solution appeared superior to the 12.5mg/1mL and 25mg/1mL (time until rescue medication = 12.44hrs). A total of 14% of patients experienced minor Adverse Drug Reactions (ADRs) of which two cases demonstrated flap necrosis. These resolved without further intervention. The study results overall indicate efficacy, safety and relative tolerability of diclofenac HPβCD used locally as a submucosal injection prior to third molar surgery (ClinicalTrials.gov-Identifier: NCT01706588).

SCHOLARONE™
Manuscripts

For Peer Review

1
2
3 **Submucosal Diclofenac for Acute Postoperative Pain in Third Molar Surgery: A**
4
5 **randomized, controlled clinical trial**
6
7

8
9
10 ¹ Patricia Gorecki, Dr. med. dent, ² Kim D. Rainsford, PhD, ¹ Pankaj Taneja, ¹ Yogesh
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

dent.

¹ The School of Dentistry, Institute of Clinical Sciences, University of Birmingham,
Birmingham Dental Hospital Edgbaston, B5 7EG, UK

² Biomedical Research Centre, Sheffield Hallam University, Sheffield, S1 1WB, UK

Address for Correspondence:

Professor Thomas Dietrich,
The School of Dentistry,
Birmingham Dental Hospital,
Institute of Clinical Sciences,
University of Birmingham,
5 Mill Pool Way,
Edgbaston, Birmingham, B5 7EG, England, UK
Tel: 0044-1214665495
Email: t.dietrich@bham.ac.uk

1
2
3 This study was funded by Institute Biochimique SA (IBSA), Lugano, Switzerland.
4
5
6

7 No conflict of interest.
8
9

10
11
12 Clinical Trial Registration: ClinicalTrials.gov identifier NCT01706588
13
14

15
16 Abstract word count: 296
17

18 Manuscript word count (Introduction – Discussion): 3198
19

20 Total word count (Abstract – Acknowledgements): 3584
21

22 Number of tables: 2
23

24 Number of figures: 3
25

26 Number of references: 38
27
28
29
30
31

32 Short (running) Title: SC hydroxypropyl- β -cyclodextrin – Diclofenac Na
33
34
35

36 Keywords: diclofenac sodium, hydroxypropyl- β -cyclodextrin, dental surgery, dental
37 pain, submucosal injection, NSAIDs
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Diclofenac sodium is a widely used non-steroidal anti-inflammatory drug (NSAID) for relief of inflammatory pain. A recent formulation combines this drug with hydroxypropyl- β -cyclodextrin (HP β CD) to improve its solubility and to enable subcutaneous administration. Previous studies confirmed the efficacy of this combination. This study's aim was to evaluate the efficacy, safety and local tolerability of diclofenac HP β CD administered as a local submucosal injection prior to lower third molar surgery. We conducted a prospective, randomised, double-blind, placebo-controlled, parallel-group phase II single centre study. **Seventy-five** patients requiring mandibular third molar surgery were randomised into one of five groups: 5mg/1mL diclofenac HP β CD, 12.5mg/1mL diclofenac HP β CD, 25mg/1mL diclofenac HP β CD, 50mg/1mL diclofenac HP β CD or 1mL placebo. The respective study drug was injected into the mucosal tissue surrounding the surgical site prior to surgery following achievement of local anaesthesia. The primary outcome measure was the Area Under the Curve (AUC) of cumulative pain scores over the time from end of surgery to 6 hours post-surgery. This demonstrated a global treatment effect between the active groups and placebo, hence confirming the study drug's efficacy ($p=0.0126$). Secondary outcome measures included the time until onset of pain and the time until patients required rescue medication, both showing statistical significance of the study drug compared to placebo ($p<0.0161$ and $p<0.0001$, respectively). The time until rescue medication ranged between 7.8hrs (for 25mg/1mL diclofenac HP β CD) and 16hrs (for 50mg/1mL diclofenac HP β CD). Interestingly, the 5mg/1mL solution appeared superior to the 12.5mg/1mL and 25mg/1mL (time until rescue medication = 12.44hrs). A total of 14% of patients experienced minor Adverse Drug Reactions (ADRs) of which two cases demonstrated flap necrosis. These

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

resolved without further intervention. The study results overall indicate efficacy, safety and relative tolerability of diclofenac HP β CD used locally as a submucosal injection prior to third molar surgery (ClinicalTrials.gov-Identifier: NCT01706588).

For Peer Review

Introduction

Diclofenac is a well-established non-selective non-steroidal anti-inflammatory drug (NSAID). Due to its anti-inflammatory, anti-pyretic and analgesic properties it is commonly used to treat acute/chronic pain, and inflammation (Barden et al. 2004; Blair and Plosker 2015; Gan 2010; Hersh et al. 2004; Moore 2007; Moore et al. 2015c; Sengupta et al. 1985). Diclofenac sodium's acidic form is poorly soluble (Sengupta et al. 1985) and therefore available as the sodium salt with pharmaceutically acceptable solvents, e.g. propylene glycol and benzyl alcohol to enable intramuscular (IM) and intravenous administration. Recent formulations use the complexing agent hydroxypropyl- β -cyclodextrin (HP β CD), serving as a solubility enhancer and facilitating smaller volumes for subcutaneous (SC) or submucosal application (Albers and Muller 1995; Blair and Plosker 2015), with previous studies confirming its successful and safe SC use (Chiarello et al. 2015; Dietrich et al. 2014; Zeitlinger et al. 2012).

Local submucosal drug injection is well-established with local anaesthetics, but otherwise rarely used. The submucosal injection of dexamethasone (Chen et al. 2017; Moraschini et al. 2016; Saravanan et al. 2016) in the context of lower third molar (LM3) surgery is a notable exception. Submucosal injection of analgesics has been described with ketorolac in endodontic pain management (Penniston and Hargreaves 1996) and tramadol in LM3 surgery (Cecchetti et al. 2014), combining the advantages of parenteral drug administration with an administration route that every dentist will be comfortable with. Both studies evaluated standard analgesic doses of the respective analgesic drug.

However, we hypothesized that local submucosal injection of diclofenac may achieve analgesia at markedly lower than standard analgesic doses, taking advantage of high

1
2
3 concentrations locally at the site of tissue insult. This would be an attractive novel
4
5 concept, potentially achieving analgesia while minimising side-effects. We planned
6
7 the present study to meet two objectives; (i) to provide proof-of-principle or otherwise
8
9 of low dose local analgesia and (ii) to evaluate the potential for submucosal
10
11 diclofenac HP β CD as a pre-emptive analgesic in LM3 surgery, as this would have
12
13 immediate clinical application, if effective. The aim of the present study was therefore
14
15 to investigate the efficacy, local tolerability and safety of pre-emptive submucosal
16
17 injection of different diclofenac HP β CD doses for postoperative analgesia in a phase-
18
19 II, proof-of-principle study.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and Methods

Study design

This investigator-initiated trial was a prospective, randomised, double-blind, placebo-controlled, parallel-group, phase-II single-centre study, conducted at The School of Dentistry, University of Birmingham and the Birmingham Dental Hospital, Birmingham, UK. Ethical approval was obtained by the Ethics Committee, Office for Research Ethics Committees Northern Ireland. The trial adhered to the Declaration of Helsinki and the International Conference on Harmonisation (ICH) consolidated Guideline on Good Clinical Practice (GCP).

Patients (aged 18 to 65), referred for the surgical removal of a LM3 under local anaesthesia (LA) requiring osteotomy, were eligible to participate (please see online appendix for full list of inclusion/exclusion criteria). Written informed consent had to be provided to be enrolled.

Intervention

Patients received one of four diclofenac HP β CD (Akis®/Dicloin®, IBSA, Lugano, Switzerland) doses (50mg/1mL, 25mg/1mL, 12.5mg/1mL or 5mg/1mL), or 1ml placebo (sterile water, Appendix Figure 1).

Randomisation, allocation concealment and blinding

The investigational drug and preparation instructions were supplied packed in identical, sealed boxes, numbered sequentially according to a pre-defined, computer-generated randomisation list in blocks of 10 (i.e., with two kits for each treatment dose level). No stratification was used. None of the investigators were aware of the randomisation method for the duration of the study to minimise risk of selection bias.

1
2
3 Following confirmation of all eligibility criteria on the surgery day, the next available
4 randomisation number was allocated to the patient. A single trained study-team
5 member (PT), not involved in any other study procedure, opened the corresponding
6 study medication pack and prepared the syringe for injection in a separate room.
7
8 Placebo, 25mg and 50mg ampoules appeared identical; however, 5mg and 12.5mg
9 formulations were prepared by diluting a 25mg ampoule with water for injection, with
10 relevant instructions being contained in the medication pack. All 1mL syringes were
11 delivered unmarked to the surgeon for administration. Neither the surgeon nor any
12 other study-team member was made aware of its contents.
13
14
15
16
17
18
19
20
21
22
23
24

25 Surgery and follow-up

26
27 Experienced Oral Surgeons performed the LM3 removal within 30 days of the
28 screening visit using a standard surgical protocol (see Appendix). The study
29 medication was injected in three sites buccal to the LM3 (approximately equal
30 distance apart, about 0.33mL per site), following achievement of LA.
31
32
33
34
35

36 During the postoperative 6-hour-observational period at the investigational site pain
37 measurements (using a 0-100mm Visual Analogue Scale (VAS)), the amount of
38 rescue medication (RM) consumed (i.e. 500mg paracetamol tablets) and surgical site
39 appearance regarding bleeding, local irritancy/tolerability were recorded. Patients
40 were then discharged and continued to make hourly pain ratings and recorded any RM
41 intake in a postoperative diary for a further 6 hours. From the day after surgery,
42 patients recorded the RM amount and an overall pain rating for each postoperative
43 day (using a 0-100mm VAS) on a daily basis for one week.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Patients returned for two follow-up visits (=day 2 and 7 post-surgery) to assess
4 postoperative extra-oral swelling, trismus and wound healing and verify RM
5 consumption.
6
7
8

9
10 Where required, extractions of any additional teeth were performed outside the trial.
11

12 13 14 Baseline/Surgical Data

15
16 A number of demographic, lifestyle and surgical data were collected at the respective
17 study visits (see Appendix).
18
19

20 21 22 Outcome measures and statistical analyses

23
24 The primary endpoint was the Area Under the Curve (AUC) of pain scores over time
25 (assessed using 0-100mm VAS), from end of surgery until 6 hours post-surgery
26 compared between treatment groups.
27
28
29

30
31 Assuming a standard deviation of 20mm and a mean difference (over the 6 hours)
32 between groups of 25mm, a sample size of 12 patients per group would be required
33 for two-by-two comparisons at $\alpha=0.05$ and 80% power. Therefore, 15 patients per
34 group were considered sufficient to preliminarily investigate the treatment's efficacy.
35
36
37
38
39

40
41
42 The following secondary endpoints were evaluated (see Appendix for further details):
43

- 44
45 • AUC of pain scores over the 12-hour-observation period post-surgery
- 46
47 • Time to onset of pain and time to RM
- 48
49 • Extra-oral swelling and trismus 6 hours post-surgery, on day 2 and 7
- 50
51 • Peak-Pain-Intensity and RM consumption
- 52
53 • Cumulative proportions of patients using RM over the 6-hour-in-clinic-
54 observation period
55
56
57
58
59
60

- Adverse events

Prespecified analysis plan

Baseline/surgical characteristics were summarised by treatment group to evaluate whether the groups were balanced at randomisation, with mean/standard deviation used for continuous measures and number/percentage for categorical variables.

Baseline characteristics were compared between the study groups using ANOVA models and Fisher's exact test.

Missing VAS pain scores or values after RM for the timed assessments in the 12h-postoperative period were replaced by using a linear interpolation method. For this purpose, the linear trend between the last two valid VAS scores was used to replace the missing value. Patients' pain ratings on postoperative days were not replaced, irrespective of timing of RM intake.

Three populations were considered for analysis, Intention-To-Treat (ITT), Per-Protocol (PP) and Safety Population (see Appendix for details).

The primary endpoint analysis was conducted using both ITT and PP. Additionally to the unadjusted analyses, a multivariable analysis was performed, adjusting for BMI, amount of bone removal and gender in the ANOVA model. Post-hoc testing for pairwise comparisons between active and placebo groups did not adjust for multiple comparisons.

All other endpoints were analysed using the ITT principle. Safety variables (AEs) were assessed using the Safety Population.

Treatment effect estimates were reported with 95% confidence intervals and statistical tests performed at $\alpha=0.05$.

Results

We screened 80 patients between January and May 2013. Out of the 75 randomised patients, 15 each were allocated to the 5mg, 12.5mg and 25mg diclofenac HP β CD group, 14 to the 50mg HP β CD group and 16 to placebo (Appendix Figure 1).

Protocol violations

Two patients were excluded from the PP population due to major protocol violations, i.e. missing or delayed (=delay \geq 15mins from scheduled time) pain measurements, which occurred in the 6-hour post-surgery period.

Demographic/surgical characteristics

Demographic and surgical characteristics were overall well-balanced between study groups (Table 1).

Efficacy variables

Primary outcome measure

We found a global treatment effect in both ITT and PP populations ($p=0.0126$ and $p=0.0057$, respectively). In contrast, no statistically significant differences were found between the active study arms (Table 2, Figure 1).

Adjustment for sex, BMI and amount of bone removal as covariates, also confirmed a global treatment effect between active and placebo arms ($p=0.0188$). Likewise, no statistically significant difference was noted between the diclofenac groups. Also, none of the covariates exerted an influence on the primary variable.

Secondary outcome measures

1
2
3 The AUC of VAS scores over the 12-hour postoperative period revealed similar
4 results to the 6-hour postoperative period with the Least Square Means (LSMs) being
5 lower in the active groups compared with placebo ($p=0.0471$). A global treatment
6 effect was seen between the diclofenac groups and placebo apart from the comparison
7 between 25mg diclofenac HP β CD and placebo ($p=0.1093$). No statistically significant
8 differences were observed between active treatment groups (Table 2, Figure 1).
9

10
11 The active groups exhibited longer time until pain onset compared to placebo
12 ($p=0.0161$ for overall treatment effect). Again, no statistical differences were found
13 between diclofenac groups (Table 2, Figure 2).
14

15
16 The time until first RM was significantly shorter in the placebo group compared to the
17 active treatment groups, demonstrating again a global treatment effect ($p<0.0001$).
18 Between the active groups no statistically significant differences were observed
19 (Table 2, Figure 3).
20

21
22 The cumulative proportion of patients taking RM over the 6-hour-period post-surgery
23 was higher in placebo compared with the diclofenac groups ($p=0.0483$) (Table 2).
24

25
26 Peak-Pain-Intensity analysis showed no global treatment effect ($p=0.8595$). Likewise,
27 evaluation of trismus revealed no statistically significant differences between active
28 groups and placebo, measured at 6 hours ($p=0.1691$), 2 days ($p=0.5428$) and 7 days
29 ($p=0.6260$) post-surgery. Similar findings were observed for the extra-oral swelling
30 measured at 6 hours ($p=0.3855$) and 2 days ($p=0.5933$). However, a global treatment
31 effect was noted at 7 days after surgery, with a small but statistically significant
32 difference in favour of the diclofenac groups compared to placebo ($p=0.0214$) (Table
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2).

Safety/tolerability

1
2
3 AEs and Adverse Drug Reactions (ADRs=AEs occurring after injection of study drug
4 and with causal relationship to study drug, as judged by investigator) were monitored
5
6
7 throughout the study period. The causal relationship between AEs and the study drug
8
9
10 was assessed at the time when the event occurred.

11
12 The number of patients experiencing at least one AE was 8 (=53.3%) in the 5mg
13
14 Diclofenac group, 9 (=60%) in the 12.5mg, 8 (=53.3%) in the 25mg and 5 (=35.7%)
15
16 in the 50mg group. Six (=37.5%) AEs were reported amongst placebo patients
17
18 (Appendix Table 1). The number of participants experiencing AEs did not differ
19
20 significantly between groups. The most frequently occurring AEs were headache,
21
22 vomiting and facial swelling (Appendix Table 2).

23
24 The percentage of ADRs was 13.3% in both the 5mg and 12.5mg Diclofenac group,
25
26 33.3% in the 25mg and 14.3% in the 50mg group. Placebo group patients did not
27
28 report any ADRs (Appendix Table 1). The most frequent ADRs were injection site
29
30 reactions, i.e.pain or swelling (Appendix Table 3). Two cases of flap necrosis were
31
32 observed during the post-operative observation period. One mild ulceration arose in
33
34 the 25mg group at the 2-day review appointment and one moderate ulceration was
35
36 observed in the 50mg group at the 7-day review appointment (Appendix Figure 2 and
37
38 3). These resolved spontaneously, without requiring any countermeasures. The
39
40 number of ADRs did not differ significantly between groups.
41
42
43
44

45 No Serious Adverse Events (SAEs) were recorded.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

This trial aimed at evaluating the safety, tolerability and efficacy of varying doses of diclofenac HP β CD (5mg, 12.5mg, 25mg, 50mg) injected locally prior to LM3 surgery.

The choice of diclofenac sodium as an anti-inflammatory analgesic for relief of mild-moderate dental pain is supported by (a)extensive studies reported from the Cochrane database (Barden et al. 2004; Moore 2007; Moore et al. 2015b; Moore et al. 2015c) showing this drug's effectiveness in dental pain with low AE incidence encountered with other NSAIDs and analgesics (Gan 2010; Moore et al. 2015a); (b)rapid absorption from oral/parenteral preparations and other favourable pharmacokinetic properties (Sengupta et al. 1985) as well as its ability to accumulate into the cerebrospinal fluid and pain inhibition in the central nervous system (Bjorkman and Elam 1993; Kokki et al. 2008); and (c)its novel mechanism of analgesia involving selective effects on ion channels (Duan et al. 2012; Gwanyanya et al. 2012) quite separate from its well-known actions as a potent inhibitor of cyclo-oxygenases and inflammatory-pain-producing prostaglandins (Gan 2010; Rainsford 2015), lipoxygenases (Gan 2010), nitric oxide-cGMP anti-nociceptive pathway activation and NMDA-receptor analgesia (Gan 2010). Some of these actions delineate diclofenac from other NSAIDs and may contribute to its potent effects as an acute pain-relieving drug.

All four drug dose levels produced significantly superior effects compared with placebo in preventing pain during the 6-hour post-surgical observation period in terms of pain intensity levels, time until pain onset and time to first RM intake. The results are consistent with findings from previous studies showing the efficacy of the

1
2
3 parenterally administered sodium diclofenac HP β CD formulation (Blair and Plosker
4
5 2015; Chiarello et al. 2015; Dietrich et al. 2014).
6

7
8 No dose-dependent effects were observed in the four active groups in any of the
9
10 evaluated endpoints. The lack of dose-dependency could be related to zero-order
11
12 kinetics that may be apparent with the localised intra-mucosal delivery of high
13
14 concentrations of the drugs. Zero-order kinetics have been observed with several
15
16 drugs administered subcutaneously, including those from controlled-release systems
17
18 (Cho et al. 1982; Hill et al. 2012; Liu et al. 2007; Mei et al. 2010). Interestingly, the
19
20 5mg dose demonstrated slightly better analgesic efficacy over the 6- and 12-hour
21
22 postoperative evaluation period, although this was not significantly different from that
23
24 observed with the other dose levels. Also, the time until pain onset and RM was
25
26 longer than in the 12.5mg and 25mg group. The concept of locally/sub-mucosally
27
28 injected analgesics is a fairly unexplored territory. The local pharmacokinetic profile
29
30 of submucosal diclofenac HP β CD is not known. Comparing the pharmacodynamic
31
32 responses involving pain relief in the present and previous studies (Dietrich et al.
33
34 2014) with pharmacokinetic data is only possible in relation to the SC administration
35
36 route of HP β CD diclofenac into the thigh. Thus, previous studies have shown
37
38 essentially bioequivalence of 75mg/mL of this formulation when given SC with that
39
40 when given IM and similar to that with diclofenac sodium as Voltaren[®] given IM
41
42 (Zeitlinger et al. 2012). The drug is rapidly absorbed with peak concentrations being
43
44 achieved from SC and IM administration of HP β CD diclofenac at about 1hr, while
45
46 those from IM diclofenac sodium were evident at 0.45hr suggesting that the HP β CD
47
48 may act as a moderate slow-release system. The peak diclofenac concentrations from
49
50 HP β CD diclofenac are slightly higher following IM compared with both SC
51
52 administered drugs (Zeitlinger et al. 2012). Overall, however, both formulations
53
54
55
56
57
58
59
60

1
2
3 achieve similar absorption when administered as the sodium salt or the HP β CD
4 formulation. The volumes of distribution, median residence time and elimination half-
5 life are comparable among the formulations and suggest that the drug is rapidly
6 distributed and eliminated from both formulations. Therefore, an alternative
7 explanation may be that in the context of the dental pain impaction model, a low dose
8 of 5mg is as efficacious as the higher doses. However, topically applied solutions
9 (e.g. Voltaren®) demonstrate a 10x delayed maximal plasma concentration (Altman et
10 al. 2015), and if submucosal application showed a similarly delayed effect the here
11 observed findings could be explained in this way. Furthermore, the vasoconstrictor in
12 the LA, administered immediately before the submucosal diclofenac injection, may
13 also have resulted in a delay of systemic distribution of the drug. Hence, the analgesic
14 effects of submucosal diclofenac observed in the present study could be attributable to
15 local or systemic drug effects, or a combination of both.

16
17 We found no evidence for submucosal HP β CD diclofenac injection to have
18 meaningful efficacy as a pre-emptive analgesic (i.e., having analgesic efficacy beyond
19 5.5 half-lives), as there were no clinically important differences in terms of analgesic
20 consumption or pain levels over the postoperative week (data not shown).

21
22 We evaluated the submucosal HP β CD diclofenac's efficacy in a modified (pre-
23 emptive) dental pain impaction model for several reasons. Firstly, we were interested
24 in evaluating an approach that would be suitable for use in clinical practice, as LM3
25 surgery is usually provided as an outpatient procedure and patients would not be able
26 to inject themselves intra-orally postoperatively. Secondly, previous studies have
27 shown that SC injections may cause some pain/discomfort, which would be
28 minimised with a pre-emptive approach as it allowed submucosal injection following
29 LA.

1
2
3 The main reported ADRs were injection site reactions, i.e.pain or swelling, reported in
4
5 14.6% of active group patients, which concurs with previous evaluations (Blair and
6
7 Plosker 2015; Dietrich et al. 2014); although this was somewhat surprising given that
8
9 the injection was given following LA. Previous studies have shown that there were no
10
11 serious adverse reactions following SC administration of sodium diclofenac HP β CD
12
13 at three dose levels of 25, 50 and 75mg/mL (Dietrich et al. 2014; Zeitlinger et al.
14
15 2012). Furthermore, Salomone et al.(Salomone et al. 2014) have shown that there are
16
17 few subjects that showed local reactions to 50mg sodium diclofenac HP β CD at the
18
19 injection sites in the abdomen, gluteus and quadriceps muscles, with all local
20
21 reactions being mild-moderate and disappearing by 10mins (i.e.hardening) or 30mins
22
23 (i.e.swelling and redness).
24
25
26

27
28 In the present study, a flap necrosis was observed in two subjects, one in the 25mg
29
30 and one in the 50mg group (Appendix Figures 2/3). These were highly unusual and
31
32 not observed previously by the investigators in LM3 surgery. Both resolved without
33
34 further interventions and without any sequelae. Among the rare adverse skin reactions
35
36 that have been reported being associated with parenteral injection of diclofenac
37
38 (Dadaci et al. 2015; Kilic et al. 2014; Nischal et al. 2009) and other drugs (Seremet et
39
40 al. 2015), antibiotics (Alkan Bozkaya et al. 2016) and vaccines (Rygnestad and Kvam
41
42 1995; Stefano et al. 2017; Wronecki and Czernik 1981) is the Nicolau syndrome
43
44 (Livedoid dermatitis or *Embolia cutis medicamentosa*). This was first reported in 1924
45
46 by Freudenthal (James et al. 2015; Kilic et al. 2014; Nischal et al. 2009) and is a rare
47
48 iatrogenic condition characterised by an immediate erythematous skin reaction
49
50 following injection or ischaemic reaction (pallor) sometimes with a reticular pattern
51
52 leading to necrosis of the skin and underlying tissue which can be severe and lead to
53
54 disfigured scarring (James et al. 2015). We believe that the two occurrences of flap
55
56
57
58
59
60

1
2
3 necrosis could be unusual mucosal manifestations of Nicolau syndrome. Although
4
5 previous reports on Nicolau syndrome have implicated diclofenac itself, we cannot
6
7 rule out HP β CD as a possible cause.
8

9
10 The results of the present study have to be cautiously interpreted due to the limited
11
12 sample size of this phase-II study, which unsurprisingly resulted in some chance
13
14 imbalances between groups in terms of patient and surgical characteristics. Thus,
15
16 confounding by these and other unmeasured factors has to be considered.
17

18
19 Overall, this study indicates efficacy, safety and relative tolerability of diclofenac
20
21 HP β CD as a local submucosal analgesic. The study provides evidence in support of
22
23 the novel concept of low-dose local analgesia for the first time. Further studies should
24
25 include investigation of the study drug's local pharmacokinetics, and larger phase-III
26
27 trials are required to confirm efficacy and safety of low-dose submucosal analgesia
28
29 for acute pain management.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Authors' contributions

TD designed research. TD, PT, YB, DP, DS and BA conducted research. PG, KR and

TD wrote the paper. TD had primary responsibility for final content.

All authors read and approved the final manuscript.

Acknowledgements

This study was funded and sponsored by Institute Biochimique SA (IBSA), Lugano, Switzerland. We would like to thank Arturo Lanzarotti for statistical support.

TD has received grant funding (to the University of Birmingham) from IBSA, and TD and KR have received consultancy/lecture fees from IBSA. All other authors report no conflicts of interest.

References

- Albers E, Muller BW. 1995. Cyclodextrin derivatives in pharmaceuticals. *Crit Rev Ther Drug Carrier Syst.* 12(4):311-337.
- Alkan Bozkaya T, Demirel G, Ormeci T, Al S, Cakar E, Tastekin A, Turkoglu H. 2016. Anticoagulant and vasodilator therapy for nicolau syndrome following intramuscular benzathine penicillin injection in a 4 year old boy. *Arch Argent Pediatr.* 114(3):e184-186.
- Altman R, Bosch B, Brune K, Patrignani P, Young C. 2015. Advances in nsaid development: Evolution of diclofenac products using pharmaceutical technology. *Drugs.* 75(8):859-877.
- Barden J, Edwards J, Moore RA, McQuay HJ. 2004. Single dose oral diclofenac for postoperative pain. *Cochrane Database Syst Rev.* (2):CD004768.
- Bjorkman R, Elam M. 1993. Diclofenac evaluated in a human experimental model of central pain. *Pain.* 54(2):197-202.
- Blair HA, Plosker GL. 2015. Diclofenac sodium injection (akis((r)), dicloin ((r))): A review of its use in the management of pain. *Clin Drug Investig.* 35(6):397-404.
- Cecchetti MM, Negrato GV, Peres MP, Deboni MC, Naclerio-Homem Mda G. 2014. Analgesic and adjuvant anesthetic effect of submucosal tramadol after mandibular third molar surgery. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 117(3):e249-254.
- Chen Q, Chen J, Hu B, Feng G, Song J. 2017. Submucosal injection of dexamethasone reduces postoperative discomfort after third-molar extraction: A systematic review and meta-analysis. *J Am Dent Assoc.* 148(2):81-91.
- Chiarello E, Bernasconi S, Gugliotta B, Giannini S. 2015. Subcutaneous injection of diclofenac for the treatment of pain following minor orthopedic surgery (direct study): A randomized trial. *Pain Pract.* 15(1):31-39.
- Cho MJ, Kurtz RR, Lewis C, Machkovech SM, Houser DJ. 1982. Metronidazole phosphate--a water-soluble prodrug for parenteral solutions of metronidazole. *J Pharm Sci.* 71(4):410-414.
- Dadaci M, Altuntas Z, Ince B, Bilgen F, Tufekci O, Poyraz N. 2015. Nicolau syndrome after intramuscular injection of non-steroidal anti-inflammatory drugs (nsaid). *Bosn J Basic Med Sci.* 15(1):57-60.
- Dietrich T, Leeson R, Gugliotta B, Petersen B. 2014. Efficacy and safety of low dose subcutaneous diclofenac in the management of acute pain: A randomized double-blind trial. *Pain Pract.* 14(4):315-323.
- Duan KZ, Xu Q, Zhang XM, Zhao ZQ, Mei YA, Zhang YQ. 2012. Targeting a-type k(+) channels in primary sensory neurons for bone cancer pain in a rat model. *Pain.* 153(3):562-574.
- Gan TJ. 2010. Diclofenac: An update on its mechanism of action and safety profile. *Curr Med Res Opin.* 26(7):1715-1731.
- Gwanyanya A, Macianskiene R, Mubagwa K. 2012. Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels. *J Pharm Pharmacol.* 64(10):1359-1375.

- 1
2
3 Hersh EV, Levin LM, Adamson D, Christensen S, Kiersch TA, Noveck R, Watson G,
4 2nd, Lyon JA. 2004. Dose-ranging analgesic study of prosorb diclofenac
5 potassium in postsurgical dental pain. *Clin Ther.* 26(8):1215-1227.
- 6 Hill A, Geissler S, Weigandt M, Mader K. 2012. Controlled delivery of
7 nanosuspensions from osmotic pumps: Zero order and non-zero order
8 kinetics. *J Control Release.* 158(3):403-412.
- 9 James WD, Berger TG, Elston DM. 2015. Andrew's diseases of the skin. *Clinical*
10 *dermatology.* WB Saunders.
- 11 Kilic I, Kaya F, Ozdemir AT, Demirel T, Celik I. 2014. Nicolau syndrome due to
12 diclofenac sodium (voltaren(r)) injection: A case report. *J Med Case Rep.*
13 8:404.
- 14 Kokki H, Kumpulainen E, Laisalmi M, Savolainen J, Rautio J, Lehtonen M. 2008.
15 Diclofenac readily penetrates the cerebrospinal fluid in children. *Br J Clin*
16 *Pharmacol.* 65(6):879-884.
- 17 Liu Y, Lu WL, Wang JC, Zhang X, Zhang H, Wang XQ, Zhou TY, Zhang Q. 2007.
18 Controlled delivery of recombinant hirudin based on thermo-sensitive
19 pluronic f127 hydrogel for subcutaneous administration: In vitro and in
20 vivo characterization. *J Control Release.* 117(3):387-395.
- 21 Mei L, Bao J, Tang L, Zhang C, Wang H, Sun L, Ma G, Huang L, Yang J, Zhang L et al.
22 2010. A novel mifepristone-loaded implant for long-term treatment of
23 endometriosis: In vitro and in vivo studies. *Eur J Pharm Sci.* 39(5):421-
24 427.
- 25 Moore N. 2007. Diclofenac potassium 12.5mg tablets for mild to moderate pain
26 and fever: A review of its pharmacology, clinical efficacy and safety. *Clin*
27 *Drug Investig.* 27(3):163-195.
- 28 Moore RA, Derry S, Aldington D, Wiffen PJ. 2015a. Adverse events associated
29 with single dose oral analgesics for acute postoperative pain in adults - an
30 overview of cochrane reviews. *Cochrane Database Syst Rev.*
31 (10):CD011407.
- 32 Moore RA, Derry S, Aldington D, Wiffen PJ. 2015b. Single dose oral analgesics for
33 acute postoperative pain in adults - an overview of cochrane reviews.
34 *Cochrane Database Syst Rev.* (9):CD008659.
- 35 Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L. 2015c. Non-
36 prescription (otc) oral analgesics for acute pain - an overview of cochrane
37 reviews. *Cochrane Database Syst Rev.* (11):CD010794.
- 38 Moraschini V, Hidalgo R, Porto Barboza E. 2016. Effect of submucosal injection of
39 dexamethasone after third molar surgery: A meta-analysis of randomized
40 controlled trials. *Int J Oral Maxillofac Surg.* 45(2):232-240.
- 41 Nischal K, Basavaraj H, Swaroop M, Agrawal D, Sathyanarayana B, Umashankar
42 N. 2009. Nicolau syndrome: An iatrogenic cutaneous necrosis. *J Cutan*
43 *Aesthet Surg.* 2(2):92-95.
- 44 Penniston SG, Hargreaves KM. 1996. Evaluation of periapical injection of
45 ketorolac for management of endodontic pain. *J Endod.* 22(2):55-59.
- 46 Rainsford K. 2015. Pharmacology and toxicology of ibuprofen. In: Rainsford K,
47 editor. *Ibuprofen: Discovery, development and therapeutics.* Wiley-
48 Blackwell. p. 132-236.
- 49 Rygnestad T, Kvam AM. 1995. Streptococcal myositis and tissue necrosis with
50 intramuscular administration of diclofenac (voltaren). *Acta Anaesthesiol*
51 *Scand.* 39(8):1128-1130.
- 52
53
54
55
56
57
58
59
60

- 1
2
3 Salomone S, Piazza C, Vitale DC, Cardi F, Gugliotta B, Drago F. 2014.
4 Pharmacokinetics of a new subcutaneous diclofenac formulation
5 administered to three body sites: Quadriceps, gluteus, and abdomen. *Int J*
6 *Clin Pharmacol Ther.* 52(2):129-134.
7
8 Saravanan K, Kannan R, John RR, Nantha Kumar C. 2016. A single pre operative
9 dose of sub mucosal dexamethasone is effective in improving post
10 operative quality of life in the surgical management of impacted third
11 molars: A comparative randomised prospective study. *J Maxillofac Oral*
12 *Surg.* 15(1):67-71.
13
14 Sengupta C, Aféche P, Meyer-Brunot HG, Rensing U. 1985. Diclofenac sodium. In:
15 Rainsford K, editor. *Anti-inflammatory and anti-rheumatic drugs volume*
16 *ii: Newer anti-inflammatory drugs.* CRC Press. p. 49-63.
17
18 Seremet S, Turan E, Erdemir AT. 2015. Nicolau syndrome following
19 intramuscular injection of oxytocin in pregnant women: Report of two
20 cases. *Dermatol Online J.* 21(8).
21
22 Stefano PC, Garello M, Nolte MF, Lamy P, Giglio N, Castellano V, Gentile A. 2017.
23 [nicolau syndrome induced by intramuscular injection of a hexavalent
24 vaccine in a 6-month-old girl]. *Arch Argent Pediatr.* 115(1):e13-e16.
25
26 Wronecki K, Czernik J. 1981. [the nicolau syndrome in children (author's transl)].
27 *Z Kinderchir.* 32(4):367-370.
28
29 Zeitlinger M, Rusca A, Orah A, Gugliotta B, Muller M, Ducharme MP. 2012.
30 Pharmacokinetics of a new diclofenac sodium formulation developed for
31 subcutaneous and intramuscular administration. *Int J Clin Pharmacol*
32 *Ther.* 50(6):383-390.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Figure legends
6
7
8

9
10 Figure 1 – Pain intensity over time

11 Pain intensity of the respective study groups from end of surgery until 12 hours post-
12 surgery
13
14

15 VAS = Visual Analogue Scale
16
17

18
19
20
21 Figure 2 – Time to pain onset

22 Kaplan Meier survival curve demonstrating the time until onset of pain following
23 surgery in the respective study groups
24
25
26
27

28
29
30 Figure 3 – Time to first rescue medication

31 Kaplan Meier survival curve illustrating the time until the first rescue medication was
32 consumed postoperatively in the respective study groups
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 – Baseline demographic and surgical characteristics; Continuous variables are presented as mean (SD)^c.

	5mg (n=15)	12.5mg (n=15)	25mg (n=15)	50mg (n=14)	Placebo (n=16)
Age (years)	28.33 (7.32)	27.73 (9.35)	29.73 (9.00)	27.36 (4.52)	29.81 (9.54)
Male (%)	40	60	20	43	25
BMI^a	27.46 (6.50)	24.56 (3.98)	24.11 (4.10)	27.05 (6.43)	24.47 (4.26)
Ethnicity (%)					
Caucasian	53	47	60	93	50
Black	20	20	7	0	6
Asian	27	33	26	7	31
Other	0	0	7	0	13
Preoperative LA^b dose (ml)	5.78 (0.98)	5.72 (1.04)	5.29 (1.21)	5.67 (1.22)	5.70 (1.08)
Supplemental LA (%)	7	7	27	0	6
Bone removal (%)					
Minor	33	33	40	50	44
Moderate	60	47	53	43	44
Severe	7	20	7	7	12
Duration of surgery (mins)	12.93 (5.85)	14.20 (6.74)	10.07 (5.11)	11.64 (6.48)	10.81 (5.11)
Tooth sectioning (%)	67	67	40	57	50
Lingual flap (%)	20	40	13	36	38

^a BMI = Body Mass Index

^b LA = Local anaesthetic

^c SD = Standard Deviation

Table 2 – Primary and secondary outcomes

	5mg (n=15)	12.5mg (n=15)	25mg (n=15)	50mg (n=14)	Placebo (n=16)	p-value\$
VAS ^a pain/ AUC ^b 0-6hrs (LSMs ^c , ITT ^d population), mean (SD ^e)	6843 (6259)	8833 (6331)	9998 (8080)	7290 (6509)	15539 (9280)	0.0126
<i>p-value #</i>	<i>0.0017</i>	<i>0.0144</i>	<i>0.0417</i>	<i>0.0034</i>		
VAS^a pain/ AUC^b 0-6hrs (LSMs^c, ITT^d population, multivariable ANOVA*), adjusted mean	6978	9985	10112	7733	15582	0.0188
<i>p-value #</i>	<i>0.0020</i>	<i>0.0394</i>	<i>0.0388</i>	<i>0.0049</i>		
VAS pain / AUC 0-6hrs (LSMs, PP ^f population), mean (SD)	5836 (5079)	8833 (6331)	10339 (8273)	7290 (6509)	15539 (9280)	0.0057
<i>p-value #</i>	<i>0.0005</i>	<i>0.0129</i>	<i>0.0559</i>	<i>0.0029</i>		

VAS pain/ AUC 0-12hrs (LSMs, ITT population), mean (SD)	22848 (19947)	29481 (17573)	32197 (20729)	25770 (20104)	43890 (21606)	0.0471
<i>p-value</i> #	0.0047	0.0495	0.1093	0.0160		
Time to pain onset (hrs), mean (SD)	5.88 (5.86)	4.53 (5.69)	2.88 (2.51)	9.69 (18.90)	1.91 (1.07)	0.0161
Time to first rese medication (hr, mean (SD)	12.44 (10.24)	9.03 (9.08)	7.81 (8.46)	16.05 (18.81)	2.63 (0.53)	<0.0001
Number of patients using rescue medication at 0-6hrs (%)	40	53	73	50	88	0.0483
VAS Peak Pain Intensity, mean (SD)	33.20 (21.24)	36.20 (14.73)	33.53 (16.58)	35.43 (21.54)	41.06 (30.81)	0.8595

Interincisal distance, day 2 (mm), mean (SD)	24.00 (6.89)	28.00 (6.78)	26.80 (9.86)	28.29 (6.76)	26.69 (8.95)	0.5428
Interincisal distance, day 7 (mm), mean (SD)	32.20 (7.16)	33.33 (7.98)	29.47 (8.74)	31.86 (6.40)	35.00 (8.69)	0.6260
Swelling, day 2 (cm), mean (SD)	15.18 (0.95)	15.43 (0.73)	15.09 (0.86)	15.61 (0.95)	15.07 (0.87)	0.5933
Swelling day 7 (cm), mean (SD)	14.92 (1.07)	15.29 (0.82)	14.93 (0.91)	15.47 (0.90)	14.87 (0.83)	0.0214

Continuous variables are presented as mean (SD).

The primary outcome variable (VAS score AUC 0-6hrs post-surgery) was evaluated in the ITT and PP population.

Interincisal distance was measured in mm and represents the distance between left upper and lower incisor at maximal mouth opening.

Swelling represents the tragus to chin distance in cm.

P-value for pairwise comparison between active group and placebo

\$ global p-value for treatment effect (ANOVA)

* Multivariate ANOVA included Body Mass Index (BMI), gender and amount of bone removal as covariates

^a VAS = Visual Analogue Scale

^b AUC = Area Under the Curve

^c LSMs = Least Square Means

^d ITT = Intention To Treat

^e SD = Standard Deviation

^f PP = Per Protocol

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 – Pain intensity over time




Figure 2 – Time to pain onset




Figure 3 – Time until first rescue medication

1
2
3 **Submucosal Diclofenac for Acute Postoperative Pain in Third Molar Surgery: A randomized**
4 **controlled clinical trial**
5
6
7
8
9

10 Patricia Gorecki, Kim D. Rainsford, Pankaj Taneja, Yogesh Bulsara, David Pearson, Daniel
11
12 Saund, Bilal Ahmed, Thomas Dietrich
13
14
15
16

17 **Methods**
18
19
20
21

22 **Exclusion criteria**
23

24 Females of childbearing potential were required to have a negative urine pregnancy test at
25
26 the inclusion visit and be using an appropriate contraception method throughout the study
27
28 period.
29

30 The following exclusion criteria applied:
31
32

- 33 • Patients refusing to give written informed consent or to return for control visits
- 34 • Patients enrolled in a clinical trial in the previous 3 months
- 35 • Pregnant or breast-feeding women
- 36 • Patients with an allergy to diclofenac/other NSAIDs
- 37 • Patients on medication that could affect the efficacy and/or safety outcomes
38 assessed in this trial, e.g. corticosteroids, other NSAIDs, anticoagulant/antiplatelet
39 agents or antimicrobials.
- 40 • Patients with a history of gastrointestinal disorders, coagulation disorders,
41 hepatic/renal/cardiac impairment, peripheral arterial disease or uncontrolled
42 hypertension
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Patients with major psychiatric disorders compromising study participation in the investigator's opinion
- Alcohol or drug abuse in the previous 12 months

Surgery and follow-up

Patients received an appointment for their LM3 removal within 30 days of their screening visit. Lidocaine 2% with 1:80,000 epinephrine (Septodont, Maidstone, Kent, UK) was used for LA (administered as an inferior dental nerve block and buccal infiltration). The maximum allowed dose of 8.8mL included intraoperative supplemental administration, if necessary. Once LA was achieved a 1mL submucosal injection of the study medication was given in three sites (approximately equal distance apart) buccal to the third molar area, with about 0.33mL given per site.

Experienced oral surgeons performed the surgery using a standard surgical procedure. A muco-periosteal envelope or triangular flap was raised according to the surgeon's preference, bone removal and tooth sectioning was performed using a surgical hand-piece and burs as required, the respective tooth was elevated and interrupted sutures were placed to achieve wound closure (Vicryl Rapide®, Ethicon, Johnson & Johnson Medical Ltd., Norderstedt, Germany).

Following surgery patients received standard postoperative instructions and stayed at the investigational site for 6 hours for the assessment of pain (using a 0-100mm Visual Analogue Scale (VAS)), the amount of rescue medication consumed (i.e. 500mg paracetamol tablets) and the appearance of the surgical site regarding bleeding and assessment of the local irritancy and tolerability. After the observational period participants were discharged with a box of paracetamol and a postoperative diary to record their pain levels, analgesic and other

1
2
3 concomitant medication consumption and adverse events (AEs) on a daily basis for one
4
5 week.

6
7
8 Patients were asked to return for two follow-up visits on day 2 and 7 after surgery (=visits 3
9
10 and 4) during which post-surgical extra-oral swelling and trismus, as well as wound healing
11
12 were assessed and rescue medication consumption was verified.
13

14 15 16 17 Baseline/Surgical Data

18
19 Demographic and lifestyle data were collected at the screening visit, including age, gender,
20
21 ethnicity, weight, height and Body Mass Index (BMI). On the day of surgery some surgical
22
23 measurements were collected, i.e. which LM3 was removed (left/right), whether the tooth
24
25 was removed completely (yes/no), preoperative LA dose (in mL), supplemental LA dose (in
26
27 mL), amount of bone removal (minor/moderate/severe), tooth sectioning (yes/no), raising
28
29 of lingual flap (yes/no) and duration of surgery (in min).
30
31
32
33
34
35
36
37
38

39 Prespecified analysis plan

- 40 • Intention-To-Treat (ITT)= all randomised patients receiving \geq one study medication
41
42 dose and with \geq one post-baseline efficacy evaluation;
43
44
- 45 • Per-Protocol (PP)= all ITT population patients without major protocol violation;
46
47
- 48 • Safety Population= all randomised patients receiving the study intervention.
49
50

51 52 53 Outcome measures and statistical analyses

54
55 The following secondary endpoints were evaluated:
56
57
58
59
60

- AUC of pain scores over the 12-hour-observation period post-surgery (assessed at the end of surgery, at 15mins intervals for the 6-hour-observation period on clinic and hourly for 6 hours after discharge), using an ANOVA model;
- Time to onset of pain (=pain \geq 30mm on VAS) and time to RM, using survival analysis;
- Extra-oral swelling (=distance between lower border of tragus and a point in the midline, 3cm below vermilion border of lower lip, marked in removable ink on patient's chin) and trismus (=distance between left upper and lower incisor at maximal opening, assessed using a ruler) 6 hours post-surgery, on day 2 and day 7, using an ANOVA model;
- Peak-Pain-Intensity (=highest pain intensity during the 12-hour-observation period post-surgery) and RM consumption, using an ANOVA model;
- Cumulative proportions of patients using RM over the 6-hour-in-clinic-observation period, using chi-square test;
- AE comparisons (reported as description of event, intensity (mild/moderate/severe), seriousness (serious/non-serious), date of onset/end, expectation (expected/unexpected) and correlation with study treatment (certain/probable/possible/unlikely/not related/not assessable)), using Fisher's exact test.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Results:

Appendix Table 1: AEs and ADRs occurring after injection of study medication (safety population)

Variable	5mg (n=15)	12.5mg (n=15)	25mg (n=15)	50mg (n=14)	Placebo (n=16)	Total (n=75)
Adverse Events (AEs ^a)						
Total number of AEs	23	20	25	9	15	92
Patients with at least one AE, N (%)	8 (53.3%)	9 (60%)	8 (53.3%)	5 (35.7%)	6 (37.5%)	36 (48%)
Adverse Drug reactions (ADRs ^b)						
Total number of ADRs	2	3	9	2	0	16
Patients with ADRs, N (%)	2 (13.3%)	2 (13.3%)	5 (33.3%)	2 (14.3%)	0 (0%)	11 (14.6%)

^a AEs = Adverse Event

^b ADRs = Adverse Drug Reaction

Appendix Table 2: AEs classified by PT (=preferred patient term)

AE ^a description	5mg n=15	12.5mg n=15	25mg n=15	50mg n=14	Placebo n=16
Diarrhoea, N (%)	1 (7%)	0	0	0	1 (6%)
Nausea, N (%)	1 (7%)	0	0	1 (7%)	2 (13%)
Vomiting, N (%)	2 (13%)	1 (7%)	2 (13%)	0	1 (6%)
Dizziness, N (%)	0	1 (7%)	1 (7%)	0	0
Headache, N (%)	4 (27%)	1 (7%)	2 (13%)	1 (7%)	2 (13%)
Jaw pain, N (%)	1 (7%)	4 (27%)	0	0	2 (13%)
Injection site pain, N (%)	2 (13%)	2 (13%)	5 (33%)	1 (7%)	0
(Injection site) swelling, N (%)	2 (13%)	0	2 (13%)	0	0
Flap necrosis, N (%)	0	0	1 (7%)	1 (7%)	0
Wound infection, N (%)	1 (7%)	1 (7%)	1 (7%)	0	1 (6%)
Gingival bleeding, N (%)	1 (7%)	0	1 (7%)	0	0


^a AE = Adverse Event

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Appendix Table 3: ADRs classified by PT (=preferred patient term)

ADR ^a description	5mg n=15	12.5mg n=15	25mg n=15	50mg n=14	Placebo n=16
Flap necrosis, N (%)	0	0	1 (7%)	1 (7%)	0
Injection site pain, N (%)	2 (13%)	2 (13%)	5 (33%)	1 (7%)	0
Injection site swelling, N (%)	0	0	2 (13%)	0	0

^a ADR = Adverse Drug Reaction



Supplementary Figure 1: Study Consort Flow Diagram

Eighty patients were screened for eligibility, out of which 75 were randomised and completed the randomised controlled trial.



Supplementary Figure 2: Partial flap necrosis in the 25mg/1mL HPβCD¹ diclofenac group, evident at 2-day review.

The patient was completely asymptomatic. The necrosis was present around the margins of the mucoperiosteal flap. This resolved without further intervention by the 7-day post-operative review appointment.

¹ HPβCD - hydroxypropyl-β-cyclodextrin



Supplementary Figure 3: Partial flap necrosis in the 50mg/1mL HP β CD diclofenac group evident at 7-day review.

The patient was asymptomatic and the necrosis recovered without further intervention (similar to the necrosis seen in the 25mg/1mL group – see Appendix Figure 2).

¹ HP β CD - hydroxypropyl- β -cyclodextrin

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3, 4
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5, 6
	2b	Specific objectives or hypotheses	5, 6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	7, Appendix
	4b	Settings and locations where the data were collected	7
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9, 10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	7, 8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7, 8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7, 8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	7, 8

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	8
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	9 - 11
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	10
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12
	13b	For each group, losses and exclusions after randomisation, together with reasons	12
Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
	14b	Why the trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	12
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	12, 13, Table 2
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Table 2
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	12
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	14, Suppl. Tables
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	16-19
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	15-19
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	15-19
Other information			
Registration	23	Registration number and name of trial registry	2, 4
Protocol	24	Where the full trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	2, 20

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.